A series of acquisitions by GSK, Merck & Co. and Sanofi has analysts at RBC Capital Markets optimistic about the biopharma M&A landscape. And the team has some potential targets in mind. Alnylam, Intra-Cellular Therapies, Karuna Therapeutics and Xenon Pharmaceuticals are among RBC’s top takeover targets because of a mix of commercial infrastructure, competitive data in major disease areas and proven technology, the analysts said in a Tuesday note. On the buyer side, the RBC team figured two neuroscience players, Biogen and Neurocrine Biosciences, may make a move.
Read the full article: Alnylam, Intra-Cellular among Analyst’s Top Picks for M&A as Biopharma Dealmaking Heats Up //
Source: https://www.fiercepharma.com/pharma/alnylam-intra-cellular-among-analysts-top-picks-ma-biopharma-dealmaking-warms